Compare RGTI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTI | GRFS |
|---|---|---|
| Founded | 2013 | 1940 |
| Country | United States | Spain |
| Employees | 164 | 25247 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.5B |
| IPO Year | N/A | N/A |
| Metric | RGTI | GRFS |
|---|---|---|
| Price | $19.01 | $7.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $30.78 | $10.15 |
| AVG Volume (30 Days) | ★ 26.2M | 577.4K |
| Earning Date | 05-11-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $225.06 | $4.49 |
| Revenue Next Year | $99.56 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.18 | $7.36 |
| 52 Week High | $58.15 | $11.14 |
| Indicator | RGTI | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 35.69 |
| Support Level | $14.18 | $7.39 |
| Resistance Level | $19.55 | $9.78 |
| Average True Range (ATR) | 1.41 | 0.22 |
| MACD | 0.18 | -0.06 |
| Stochastic Oscillator | 66.00 | 3.80 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.